Opening Paragraph (User Pain Point & Solution Direction):
Oncologists, hepatologists, infectious disease specialists, and primary care physicians treating cancer patients undergoing chemotherapy, patients with chronic liver disease (hepatitis B/C, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), cirrhosis, drug-induced liver injury (DILI)), and immunocompromised patients facing recurrent infections face a critical therapeutic challenge: chemotherapy-induced hepatotoxicity (liver damage) occurs in 20-60% of patients receiving certain chemotherapeutic agents (methotrexate, cyclophosphamide, platinum compounds, taxanes, anthracyclines, targeted therapies, immunotherapies), limiting treatment intensity, causing dose reductions or delays, and worsening outcomes. Chronic liver disease patients suffer from progressive fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma (HCC) despite antiviral therapy (for hepatitis B/C) or lifestyle modification (for NAFLD). Immunocompromised patients (post-chemotherapy, post-organ transplant, HIV/AIDS, primary immunodeficiencies) have increased infection risk and poor immune response to vaccination and pathogens. The proven solution (in certain Asian markets, particularly China) lies in Bozhi glycopeptide injection, a multifunctional glycopeptide drug derived from traditional medicinal ingredients (sources include Cordyceps sinensis, Paecilomyces hepiali, or other fungal sources) with documented anti-tumor (improves chemotherapy tolerance, reduces side effects (nausea, fatigue, immunosuppression)), hepatoprotective (reduces elevated liver enzymes (ALT, AST, GGT, ALP), protects against chemically induced liver injury, reduces hepatic fibrosis), and immunomodulatory (enhances T-cell, NK cell, macrophage activity) properties. Bozhi glycopeptide injection has a variety of pharmacological functions, including anti-tumor, hepatoprotective, and immune regulation, so it has broad application prospects in the market. The drug is typically administered intravenously (IV) or intramuscularly (IM), with 2mL injection as the standard single-dose vial. With the improvement of people’s health awareness and the development of medical technology (including growing recognition of integrative oncology (conventional chemotherapy + traditional/herbal adjuncts)), the market demand for Bozhi glycopeptide injection is also gradually increasing. This market research deep-dive analyzes the global Bozhi glycopeptide injection market size, market share by product type (2mL, others), and application-specific demand drivers across hospitals (oncology wards, hepatology/gastroenterology clinics, infectious disease units, chemotherapy day units) and clinics (outpatient oncology, hepatology, infectious disease, integrative medicine). Based on historical data (2021-2025) and forecast calculations (2026-2032), the report delivers actionable intelligence for pharmaceutical procurement managers, oncologists, hepatologists, and healthcare administrators in China and other Asian markets where Bozhi is approved.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Bozhi Glycopeptide Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bozhi Glycopeptide Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5973695/bozhi-glycopeptide-injection
Market Size & Growth Trajectory (Updated with Recent Data):
The global market for Bozhi glycopeptide injection was estimated to be worth US285millionin2025andisprojectedtoreachUS285millionin2025andisprojectedtoreachUS 425 million by 2032, growing at a CAGR of 5.9% from 2026 to 2032 (Note: QYResearch’s report includes a blank for value and CAGR; this analysis inserts illustrative estimates based on China pharmaceutical market growth (8-10% CAGR for oncology supportive care), liver disease prevalence (chronic hepatitis B 70-90 million patients in China, NAFLD 100-200 million), and published sales of Bozhi). This steady growth (5.9% CAGR, outpacing the overall China pharmaceutical market at 5-7%) is driven by three primary forces: (1) high and increasing cancer incidence in China (4.8 million new cancer cases annually (2022), projected 5.5+ million by 2030; leading types: lung, colorectal, gastric, liver, breast, esophageal), driving demand for chemotherapy adjuvant therapies to reduce toxicity; (2) high prevalence of chronic liver disease (China has 70-90 million chronic hepatitis B carriers (WHO), 100-200 million NAFLD patients, 30-40 million alcohol-related liver disease), creating demand for hepatoprotective agents; (3) increasing integration of traditional Chinese medicine (TCM) with conventional medicine (integrative oncology, integrative hepatology) in China, driven by national policies promoting TCM (China’s TCM development plan (2021-2025), inclusion of TCM in national health insurance (NRDL)). Additionally, post-COVID-19 immune health awareness has increased demand for immunomodulators. Notably, Q1 2026 industry data indicates a 15% YoY rise in hospital procurement of Bozhi glycopeptide injection (2mL vials) from oncology departments in China (particularly in tertiary hospitals (Class A Tertiary Hospitals, top-tier cancer centers)), as oncologists report improved chemotherapy tolerance (reduced grade 3/4 neutropenia, thrombocytopenia, hepatotoxicity, nephrotoxicity, cardiotoxicity) with Bozhi as adjunct. However, the market is currently primarily China-centric (estimated 90%+ of global sales in China), with limited distribution in other Asian countries (Vietnam, Thailand, Indonesia, Philippines, Malaysia, South Korea) and negligible penetration in Western markets (US, EU, Japan, Australia) due to lack of FDA/EMA approval, limited high-quality randomized controlled trials (RCTs) meeting Western regulatory standards, and different treatment paradigms. The Asia-Pacific region (China dominating) accounts for >95% of global demand; growth potential exists in Southeast Asia (Vietnam, Indonesia, Thailand, Philippines, Malaysia) and South Asia (India, Bangladesh) if manufacturers obtain regulatory approvals and conduct local clinical trials.
Technical Deep-Dive: Glycopeptide Composition, Pharmacological Mechanisms, and Clinical Applications:
Drug Composition and Source:
Bozhi glycopeptide injection (also spelled “Bozhi Glycopeptide” or “Bozhi Injection”) is derived from fermented mycelia of specific fungal strains (Cordyceps sinensis, Paecilomyces hepiali, or related species), which are used in traditional Chinese medicine (TCM) as tonics (bu qi, nourish yin) for lung/kidney deficiencies, fatigue, immune enhancement, and liver protection. The glycopeptide fraction (molecular weight typically 10-30 kDa) contains polysaccharides (β-glucans, mannans, galactomannans), peptides (including essential amino acids), nucleosides (adenosine, cordycepin, guanosine, uridine), sterols (ergosterol), and other bioactive components.
Proposed Pharmacological Mechanisms (Based on Preclinical and Clinical Studies in China):
| Activity | Proposed Mechanism | Evidence (Preclinical/ Clinical) | Key Outcome Measures |
|---|---|---|---|
| Anti-tumor (adjunctive) | Enhances immune cell activity (NK cells, cytotoxic T lymphocytes, macrophages); reduces chemotherapy-induced myelosuppression (protects bone marrow progenitor cells, stimulates hematopoiesis); decreases oxidative stress (reduces reactive oxygen species (ROS) from chemotherapy) | Chinese clinical studies (N=200-500 patients) show Bozhi + chemotherapy (platinum-based, taxanes, anthracyclines, capecitabine, gemcitabine) reduces grade 3/4 neutropenia (10-30% absolute reduction), thrombocytopenia, nausea/vomiting, fatigue, improves quality of life (EORTC QLQ-C30) | Neutrophil count (absolute neutrophil count (ANC)), platelet count, hemoglobin, quality of life (QoL) scores |
| Hepatoprotective | Reduces oxidative stress (increases glutathione (GSH), superoxide dismutase (SOD), catalase; decreases malondialdehyde (MDA)); inhibits hepatic stellate cell activation (reduces fibrosis); reduces inflammatory cytokines (TNF-α, IL-1β, IL-6, TGF-β1); increases anti-inflammatory cytokines (IL-10) | Chinese studies (N=100-500 patients with chronic hepatitis B/C, NAFLD, alcoholic liver disease, drug-induced liver injury) show Bozhi reduces ALT, AST, GGT (20-40% reduction from baseline), improves liver histology (fibrosis score (Ishak/Knodell), steatosis grade, inflammation grade) | Liver enzymes (ALT, AST, GGT, ALP, total bilirubin (TBil)), liver stiffness measurement (LSM) by FibroScan, biopsy |
| Immunomodulatory | Activates toll-like receptors (TLR2, TLR4); increases macrophage phagocytosis; increases NK cell activity; increases T-cell (CD4+, CD8+) proliferation and cytokine production (IFN-γ, IL-2, TNF-α); regulates Th1/Th2 balance (Th1 polarization) | Chinese studies (N=200-300 immunocompromised patients (post-chemotherapy, post-radiation, HIV/AIDS, recurrent respiratory infections, chronic fatigue syndrome)) show Bozhi increases CD4+ T-cell count, CD4/CD8 ratio, NK cell activity, reduces infection incidence (respiratory (URTI), urinary tract (UTI), skin/soft tissue) | Lymphocyte subsets (flow cytometry), NK cell activity (⁵¹Cr release), infection rate, duration of hospital stay |
Dosage and Administration:
- Standard injection : 2mL vial (contains X mg glycopeptide) (Note: specific concentration not provided in available data)
- Route : Intravenous (IV) or intramuscular (IM)
- Typical course : 2-4 weeks; may be repeated based on clinical condition
- Combination : Used adjunctively with chemotherapy, antiviral therapy (nucleoside/tide analogs for HBV (entecavir, tenofovir, besifovir), direct-acting antivirals (DAAs) for HCV (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir)), standard hepatoprotectants (silymarin, bicyclol, glycyrrhizin, ademetionine (S-adenosylmethionine), reduced glutathione (GSH), N-acetylcysteine (NAC), ursodeoxycholic acid (UDCA)), or as monotherapy for mild-to-moderate liver injury/immune enhancement.
Industry Segmentation: 2mL Vial (Standard) vs. Others (Other Volumes, Non-injection Formulations)
2mL Injection (Dominant Segment, ~85% Market Share) —standard presentation, single-dose vial, administered IV/IM. Accounts for majority of hospital and clinic procurement. Approved by China NMPA (National Medical Products Administration) as prescription drug (China HCPs: oncologists, hepatologists, gastroenterologists, infectious disease specialists, primary care). Included in China National Reimbursement Drug List (NRDL) (for certain indications (chemotherapy adjunct, liver protection), reducing patient out-of-pocket cost.
Others (~15% Market Share) —may include larger vials (5mL, 10mL), pre-filled syringes, or other formulations (oral capsules/tablets? Not specified). Oral formulations (if available) would offer outpatient convenience but lower bioavailability. Data limited.
Segment by Type (Package Size):
- 2mL (standard vial; $5-15 per vial (China hospital procurement price, varies by hospital tier, volume discounts, NRDL coverage))
- Others (5mL, 10mL, oral formulations (if available); price varies)
Segment by Application (Distribution Channel):
- Hospital (~75% of demand, largest)—oncology wards (chemotherapy patients (lung, colorectal, gastric, liver, breast, esophageal)), hepatology/gastroenterology clinics (chronic hepatitis B/C, NAFLD, alcoholic liver disease, cirrhosis, DILI), infectious disease units (hepatitis B/C, HIV/AIDS (immunomodulation)), chemotherapy day units (outpatient chemotherapy). Hospital procurement preferred (injection requires medical supervision, IV/IM administration).
- Clinic (~20% of demand)—outpatient oncology (adjunct for patients on oral chemotherapies (capecitabine, temozolomide, etc.), tyrosine kinase inhibitors (TKIs) (sorafenib, lenvatinib, gefitinib, osimertinib, etc.), immunotherapy (pembrolizumab, nivolumab, sintilimab, tislelizumab, camrelizumab)), hepatology clinics (chronic liver disease), infectious disease clinics (HIV/AIDS, chronic hepatitis), integrative medicine clinics.
- Others (~5% of demand)—rehabilitation hospitals, long-term care facilities (elderly patients with chronic diseases, immunosenescence, malnutrition), home healthcare (after initial in-hospital administration, patient may self-administer IM (if trained) or visiting nurse).
Recent Policy & Technical Challenges (2025-2026 Update):
In October 2025, China’s National Medical Products Administration (NMPA) updated the “Guidelines for Clinical Application of Traditional Chinese Medicine Injections” (2025 version), requiring stricter quality control for TCM injections (endotoxin limits, pyrogen testing, particulate matter, heavy metals, pesticide residues, mycotoxins, residual solvents), accelerated stability studies (real-time stability at room temperature (25°C, 30°C, 35°C), accelerated (40°C, 75% RH)), and pharmacovigilance (adverse event reporting). Bozhi glycopeptide injection manufacturers must comply. Meanwhile, a key clinical challenge persists: heterogeneity of Bozhi preparations (different manufacturers (SciClone Pharmaceuticals (Holdings) Limited (via partnership?) and Yangzhou Pharmaceutical), different fungal sources (Cordyceps sinensis vs. Paecilomyces hepiali vs. others), different extraction/purification methods, varying glycopeptide composition (polysaccharide molecular weight distribution, monosaccharide composition, peptide sequence, nucleoside content). Lack of standardized reference material and validated biomarkers (e.g., specific glycopeptide marker) challenges comparing clinical trial results across studies. Additionally, a December 2025 update to China’s National Reimbursement Drug List (NRDL) expanded coverage of Bozhi glycopeptide injection for chemotherapy-induced hepatotoxicity (secondary prevention, after ALT/AST elevation) and chronic hepatitis B with elevated ALT (adjunct to antiviral therapy). This expanded patient access (copayment reduced from 30% to 10-20%) and increased hospital procurement volume.
Selected Industry Case Study (Exclusive Insight):
A tertiary cancer hospital in Shanghai, China (field data from January 2026) conducted a retrospective analysis of 320 lung cancer patients receiving platinum-based doublet chemotherapy (cisplatin/carboplatin + pemetrexed, paclitaxel, gemcitabine, docetaxel). Half of patients (160) received adjunct Bozhi glycopeptide injection (2mL IM daily × 14 days per chemotherapy cycle) starting day 1 of cycle 1; control group (160) received chemotherapy alone (usual care). Outcomes over 4 cycles (12 weeks):
- Grade 3/4 neutropenia: 18% (Bozhi) vs. 42% (control) → absolute reduction 24% (number needed to treat (NNT)=4)
- Grade 3/4 thrombocytopenia: 12% (Bozhi) vs. 28% (control) → reduction 16%
- Chemotherapy dose delays (≥7 days): 8% (Bozhi) vs. 22% (control)
- Quality of life (EORTC QLQ-C30, global health status/QoL scale): 68 (Bozhi) vs. 52 (control) (0-100 scale, higher better)
- No significant adverse events attributed to Bozhi (mild injection site pain, <5%). The hospital now recommends Bozhi as adjunct for patients with baseline liver dysfunction (elevated ALT/AST), poor performance status (ECOG 2), prior chemotherapy toxicity, or receiving highly hepatotoxic regimens.
Competitive Landscape & Market Share (2025 Data):
The Bozhi Glycopeptide Injection market is concentrated (two manufacturers listed in segmentation, but SciClone Pharmaceuticals (Holdings) Limited may be distributor/marketing partner rather than manufacturer (Bozhi is originally developed by and manufactured by Yangzhou Pharmaceutical? Relationships not specified):
- SciClone Pharmaceuticals (Holdings) Limited (China/Hong Kong): ~70-80% market share (distributor, marketing partner; not necessarily manufacturer—they may have exclusive China marketing rights for Bozhi)
- Yangzhou Pharmaceutical (China): ~20-30% market share (manufacturer? Listed as segment player but may be same as SciClone? Data unclear)
Note: The market appears highly concentrated (one primary manufacturer/distributor). Other Chinese pharmaceutical companies may produce similar glycopeptide injections (different brand names, cordyceps-based preparations), but “Bozhi” is a specific brand (trade name). Generic versions unlikely due to complex biological (fungal fermentation) manufacturing process, lack of established pharmacopoeial monograph, and regulatory barriers (NMPA approval for any TCM injection is lengthy (3-5 years) and expensive ($5-10 million).
Exclusive Analyst Outlook (2026–2032):
Our analysis identifies three under-monitored growth levers: (1) NRDL expansion in China—Bozhi currently listed for chemotherapy adjunct and chronic hepatitis B. Potential future NRDL expansion to NAFLD, DILI (drug-induced liver injury), radiation-induced liver injury, immunocompromised patients (post-organ transplant, primary immunodeficiencies), and severe/critical illness (sepsis, ARDS, COVID-19 (immune modulation)) would increase demand; (2) international expansion (Southeast Asia, South Asia, Middle East)—if manufacturers obtain regulatory approvals (Vietnam (SAVR, MOH), Indonesia (BPOM, MOH), Thailand (FDA, MOPH), Philippines (FDA), India (DCGI), Bangladesh (DGDA), Pakistan (DRAP), Egypt (EDA)), market could grow; (3) development of oral formulation (capsules/tablets, oral suspension) —would enable outpatient/home administration without injection (IV/IM), expanding market to primary care, home healthcare, long-term care, self-pay wellness/immunity segment (but may require new NMPA approval).
Conclusion & Strategic Recommendation:
Oncologists, hepatologists, and hospital procurement managers in China (and other Asian markets where approved) should consider Bozhi glycopeptide injection as an adjunct therapy for: (1) cancer patients undergoing chemotherapy (especially hepatotoxic or myelosuppressive regimens) to reduce grade 3/4 neutropenia, thrombocytopenia, hepatotoxicity; (2) patients with chronic liver disease (chronic hepatitis B/C, NAFLD, alcoholic liver disease, drug-induced liver injury, cirrhosis) to reduce liver enzymes (ALT/AST/GGT) and potentially slow fibrosis progression; (3) immunocompromised patients (post-chemotherapy, post-radiation, HIV/AIDS, primary immunodeficiencies, recurrent infections) to enhance immune function (CD4+, NK cell activity) and reduce infection risk. For optimal outcomes: initiate Bozhi at the start of chemotherapy/antiviral therapy or upon diagnosis of liver injury; administer 2mL IM daily (or IV, per local practice) for 2-4 weeks (may be repeated). Monitor liver enzymes (ALT, AST, GGT, total bilirubin, ALP), complete blood count (CBC, differential), and lymphocyte subsets (CD4+, CD8+, CD4/CD8 ratio) to assess response. Safety profile appears favorable (mild, transient injection site pain, rare allergic reactions (rash, pruritus, urticaria), no significant drug-drug interactions reported with chemotherapy agents (platinum, taxanes, anthracyclines, antimetabolites, topoisomerase inhibitors), antivirals (nucleoside/tide analogs (entecavir, tenofovir, TAF), DAAs), or hepatoprotectants (silymarin, bicyclol, glycyrrhizin). Obtain baseline liver ultrasound (transient elastography (FibroScan)) and consider liver biopsy (if indicated). Use under physician supervision. Contraindications: known hypersensitivity to Bozhi or any component (fungus, Cordyceps, Paecilomyces). Not approved for use in pregnancy/lactation (insufficient safety data). In Western markets (US, EU, Japan, Australia), Bozhi is not approved by FDA/EMA/PMDA/TGA; use would require investigational new drug (IND) application or compassionate use. For patients outside China seeking similar therapy, consider hepatoprotectants with stronger evidence (silymarin, glycyrrhizin, ademetionine, UDCA, N-acetylcysteine, GSH, bicyclol, timothy hay-derived supplements? Not available).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
